Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Selmaj K, Li DKB, Hartung H-P, Hemmer B, Kappos L, Freedman MS, Stüve O, Rieckmann P, Montalban X, Ziemssen T, et al. Lancet Neurol. 2013 Aug; 12(8):756-67. Epub 2013 Jun 11. PMID: 23764350. Abstract CommentRecommendBookmarkWatch